Guest guest Posted October 2, 2004 Report Share Posted October 2, 2004 I found a press release from a company, Pain Therapeutics, forecasting a $1 billion market by using LDN for irritable bowel syndrome (IBS). This made me wonder, could a drug company lock up use of a compounded drug like naltrexone? Or can they slap a new name on it and sell it for big $$, while we still get it cheap from compounders? The good news is that research is being done on naltrexone and illness that may be influenced by opioid receptors. Here is the report on their tral of LDN for IBS: PTI-901 (low-dose naltrexone HCI) is Pain Therapeutics' novel drug candidate to treat men or women with IBS. It is believed that an imbalance of opioid activity in the gut contributes to the symptoms that comprise IBS. Such an imbalance may be triggered by emotional stress, metabolic disorders or intrinsic release of opioids from neurons in the gut. PTI-901 is the first in a new class of drugs called opioid antagonists designed to restore the balance of opioid activity in the gut. By restoring this imbalance, PTI-901 relieves abdominal pain and other symptoms frequently observed in patients with IBS. Pain Therapeutics holds exclusive, worldwide commercial rights to a family of issued patents and patent applications directed to the long-term treatment of IBS patients with proprietary opioid antagonists, such as PTI-901. Full story http://phx.corporate-ir.net/phoenix.zhtml?c=120834 & p=irol- newsArticle_print & ID=458802 & highlight= Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.